As a novel TKI, anlotinib can highly selectively inhibit C-Kit, VEGFR2, PDGFR, FGFR, and other targets, block their downstream signal transduction, play an effective role in anti-TA and tumor growth, and resolve poor effectiveness and toxic reactions. Here, KIT is linked to neoplasm.